PRECEPTORSHIP COURSE IN HEAD & NECK CANCER MANAGEMENT
National Cancer Center Hospital EastKashiwaKASHIWA, JAPAN Visit the Venue to read more
Treatment options for patients with unresectable head and neck cancer have been significantly expanded over the last few years. Combined modality treatment with concomitant chemotherapy and radiotherapy represents the standard of care for patients with advanced head and neck cancer and the introduction of new molecular targeted therapies lead to a further improvement in treatment outcomes. This activity will offer the opportunity to learn from a recognized and experienced multidisciplinary team current therapeutic options for patients with advanced and metastatic head and neck cancer. Effective interaction between the multidisciplinary team and participants will be encouraged through clinical case discussion and practical sessions dedicated to treatment planning and delivery.
After attending this live educational preceptorship course, participants will be able to:
Define the methodology of the multidisciplinary approach in the clinical management of head and neck cancer patients
Review current and novel therapeutic approaches for the treatment of head and neck cancer patients
Recognize the importance of supportive care in the treatment of patients with head and neck cancer
Medical oncologists, surgeons and radiation oncologists coming from Asia, who are experienced in managing head and neck cancer (HNC) patients and whose interest is to broaden their understanding of the multidisciplinary team approach and the current therapeutic options for patients with advanced and metastatic HNC.
M. Tahara (Japan)National Cancer Center East Hospital
This live educational preceptorship course will take place at the:National Cancer Center Hospital EastKashiwa, Chiba Prefecture, Japan
The official language of this live educational preceptorship course will be English. Simultaneous translation from Japanese to English will be provided.
For information on accommodation and registration fee please contact email@example.com
EXCEMED - Excellence in Medical Education
Salita di San Nicola da Tolentino, 1/b - 00187 Rome, Italy
Program Manager: Giovanna Rossi
T +39 06 420413 252 - F +39 06 420413 677
Specialist Medical Advisor: Cristina Raimondi
EXCEMED is a Swiss Foundation with headquarters in
14, Rue du Rhône, 1204 Geneva, Switzerland
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
In the spirit of supporting the dissemination of knowledge in head and neck cancer management, I am pleased to invite you to submit an abstract proposals for the upcoming Preceptorship course to be held in Kashiwa, Japan.
Authors are requested to send their abstract via e-mail by 3 August 2015 to the following address: firstname.lastname@example.org
A. Multidisciplinary approach in the treatment of head and neck cancer
B. Novel therapeutic approaches for head and neck cancers
C. Head and Neck cancer patients’ quality of life
Abstracts must be written in English and should not exceed 300 words. Abstract format: Title, Authors, Affiliations, Main text including background, aims, materials and methods, results and conclusions. The abstract should be structured as follows:
“Introduction”: an informative and short background of the study
“Aims”: outlining the main hypothesis and objectives of the study
“Material and Methods”: indicating the number, nature and type of cohorts or material being studied, as well as the main procedures, assays, tests or treatments performed for it
“Results”: showing the main results obtained, confirming or refuting the initial hypothesis, supported by statistics if appropriate
“Conclusions”: stating the key learning points of the study
Abbreviations can be used after defining them first. The abstract title should reflect the contents and should be no longer than 150 characters.
List the authors with family name first, followed by initials. The name of the first author is also the presenting author. Use font size 12, Times New Roman font, and line spacing 1.5. Authors are requested to disclose any financial support received and/or any potential conflict of interest at the end of the abstract. The selected abstracts will be published in the congress abstract book to be distributed on-site to all participants.
Notification of accepted abstracts will be sent by 30 September 2015.